Soft Tissue Sarcoma Update, Issue 1, 2017 (Video Program)

FDA approval of trabectedin for patients with unresectable or metastatic liposarcoma or leiomyosarcoma who experience disease progression after receiving an anthracycline regimen
2:53 minutes.

Classification, incidence and management of sarcomas

Integration of the recently FDA-approved agents trabectedin and eribulin into the treatment algorithms for metastatic liposarcoma and leiomyosarcoma

Recent FDA approval of olaratumab in combination with doxorubicin and integration into the treatment algorithm for advanced STS

Role of tyrosine kinase inhibitors and immune checkpoint inhibitors in STS